The listing will let CK Hutchison fragment Chi-Med numbers into its financial statements. Photo: Nora Tam

CK Hutchison-controlled biopharmaceutical company Chi-Med applies to list in Hong Kong

  • Controlling shareholder CK Hutchison to reduce its stake to below 50 per cent
  • Chi-Med is already listed on the AIM market of the London Stock Exchange, Nasdaq Global Select Market
Topic |   IPO

TOP PICKS

The listing will let CK Hutchison fragment Chi-Med numbers into its financial statements. Photo: Nora Tam
READ FULL ARTICLE